Annexon saw the highest growth of 1.49% in patent filings in April and 1.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.49% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Annexon‘s patent filings and grants. Buy the databook here.
Annexon has been focused on protecting inventions in United States(US) with three publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 50% filings and 33% grants. The United States(US), Denmark(DK), World Intellectual Property Organization(WIPO), and Australia(AU) patent Office are among the top ten patent offices where Annexon is filings its patents. Among the top granted patent authorities, Annexon has 33% of its grants in United States(US), 33% in Australia(AU) and 33% in Finland(FI).
Regeneron Pharmaceuticals and Immatics could be the strongest competitors for Annexon
Patents related to rare diseases lead Annexon's portfolio
Annexon has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
Alzheimer's disease related patents lead Annexon portfolio followed by lupus nephritis, and vasculitis
Annexon has highest number of patents in alzheimer's disease followed by lupus nephritis, vasculitis, antiphospholipid syndrome, and glomerulonephritis. For alzheimer's disease, nearly 2% of patents were filed and 3% of patents were granted in Q2 2024.
For comprehensive analysis of Annexon's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.